Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HuYON007
- Development stage
- Preclinical
- Lead developer
- JN Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
HuYON007 is a humanized monoclonal antibody agonist targeting Death Receptor 4 (DR4), also known as TRAIL-R1 or Tumor Necrosis Factor Receptor Superfamily Member 10A. Developed by JN Biosciences, the therapeutic utilizes the proprietary MultYmab technology to create a multimeric IgG1 antibody structure. This unique configuration is designed to overcome the limitations of traditional bivalent antibodies by effectively inducing the trimerization of DR4 on the surface of tumor cells, a necessary step for the activation of the extrinsic apoptotic signaling pathway. HuYON007 is intended to trigger programmed cell death in DR4-expressing cancer cells and is currently undergoing preclinical evaluation for the treatment of various hematological and solid malignancies.
- Other names
- anti-DR4 monoclonal antibodyanti-DR-4 monoclonal antibodyanti-DR 4 monoclonal antibodyhumanized anti-DR4 IgG agonist antibody
02
Targets
TNFRSF10A (Death receptor 4)
Beyond the preview
Go deeper on HuYON007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HuYON007.